It was previously demonstrated that the CNS-penetrant compound bryostatin-1 (bryo-1) exerts an immunomodulatory effect on myeloid-lineage innate immune cells in the periphery through its actions on protein kinase C (PKC). In a new study, researchers from Johns Hopkins University aimed to assess the potential of bryo-1 for the treatment of progressive multiple sclerosis (MS) by investigating its effect on remyelination.